Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8698-8706

  Zeitlin, Benjamin D ^a   Joo, Esther ^a   Dong, Zhihong ^a   Warner, Kristy ^a   Wang, Guoping ^b   Nikolovska Coleska, Zaneta ^a,b   Wang, Shaomeng ^a,b   Nör, Jacques E ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN BCL 2; TW 37; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL MIGRATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; APOPTOSIS; BENZAMIDES; CELL SURVIVAL; CHEMOKINE CXCL1; ENDOTHELIUM, VASCULAR; HUMANS; INTERLEUKIN-8; MICROCIRCULATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN; SULFONES;

EID: 33749023071     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3691     Document Type: Article

References (50)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Kerbel RS. Antiangiogenic drugs and current strategies for the treatment of lung cancer. Semin Oncol 2004;31: 54-60.
3. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55:15-35.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1995;1:27-31.
5. Noma H, Funatsu H, Yamashita H, et al. Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch Ophthalmol 2002;120:1075-80.
6. Pradier O, Lederer K, Hille A, et al. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter. J Cancer Res Clin Oncol 2005;131:261-9.
7. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92.
8. Soria JC, Fayette J, Armand JP. Molecular targeting: targeting angiogenesis in solid tumors. Ann Oncol 2004; 15 Suppl 4:223-7.
9. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
10. Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 2005;32:61-8.
11. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004;90:1-7.
12. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80.
13. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004; 10:6367-705.
14. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23: 3697-705.
15. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005;16:558-65.
16. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21: 3955-64.
17. Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005;436:568-72.
18. Del Vecchio S, Zannetti A, Aloj L, et al. Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. Eur J Nucl Med Mol Imaging 2003;30:879-87.
19. Vanasse GJ, Winn RK, Rodov S, et al. Bcl-2 overexpression leads to increases in suppressor of cytokine signaling-3 expression in B cells and de novo follicular lymphoma. Mol Cancer Res 2004;2:620-31.
20. Badaracco G, Venuti A, Bartolazzi A, et al. Overexpression of p53 and bcl-2 proteins and the presence of HPV infection are independent events in head and neck cancer. J Oral Pathol Med 2000;29:173-9.
21. Grace VM, Shalini JV, Lekha TT, et al. Co-overexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2003;91:51-8.
22. Cervero C, Escribano L, San Miguel JF, et al. Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. Am J Hematol 1999;60:191-5.
23. Del Bufalo D, Trisciuoglio D, Scarsella M, et al. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 2003;22:8441-7.
24. Trisciuoglio D, Iervolino A, Zupi G, et al. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 2005;16:4153-62.
25. Tortora G, Caputo R, Damiano V, et al. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Clin Cancer Res 2001;7:2537-44.
26. Alladina SJ, Song JH, Davidge ST, et al. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res 2005;42:337-47.
27. Nor JE, Christensen J, Liu J, et al. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001;61:2183-8.
28. Karl E, Warner K, Zeitlin B, et al. Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines. Cancer Res 2005;65: 5063-9.
29. Ruiz-Vela A, Opferman JT, Cheng EH, et al. Proapoptotic BAX and BAK control multiple initiator caspases. EMBO J 2005;6:379-85.
30. Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 2003;304: 437-44.
31. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
32. Nör JE, Hu Y, Song W, et al. Ablation of microvessels in vivo upon dimerization of iCaspase-9. Gene Ther 2002;9:444-51.
33. Nör JE, Christensen J, Mooney DJ, et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999;154: 375-84.
34. Nör JE, Peters MC, Christensen JB, et al. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 2001;81:453-63.
35. Li A, Dubey S, Varney ML, et al. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3369-76.
36. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
37. Ito T, Deng X, Carr B, et al. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997; 272:11671-3.
38. Muhammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005;4:13-21.
39. L are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2004;315:771-9.
40. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
41. Pollack A, Cowen D, Troncoso P, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003;97:1630-8.
42. Saleh HA, Jackson H, Banerjee M. Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia. Appl Immunohistochem Mol Morphol 2000;8:175-82.
43. Real PJ, Cao Y, Wang R, et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 2004;64: 7947-33.
44. Becattini B, Kitada S, Leone M, et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol 2004;11:389-95.
45. Oliver CL, Bauer JA, Wolter KG, et al. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004;10: 7757-63.
46. Wang LL, Li JJ, Zheng ZB, et al. Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells. Eur J Pharmacol 2004; 502:1-10.
47. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81.
48. Lickliter JD, Wood NJ, Johnson L, et al. HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. Leukemia 2003;17:2074-80.
49. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
50. Dienst A, Grunow A, Unruh M, et al. Specific occlusion of murine and human tumorvasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 2005;97:733-47.